Resolve Therapeutics is pioneering safe, targeted therapies for underserved patients with autoimmune diseases. Our lead program, RSLV-132, is designed to prevent chronic, systemic inflammation that may cause organ damage and the symptoms associated with autoimmune diseases. RSLV-132 is a first-in-class RNase-Fc fusion protein being developed to treat patients with lupus and Sjögren’s syndrome. We have successfully completed a Phase 2a study in SLE (insert link to Dec 8, 2020 press release) and will be initiating a Phase 3 study in Sjögren’s syndrome in 2022.

Management Team


Chief Executive Officer Member,
Board of Managers

James Posada, Ph.D., is founder and Chief Executive Officer…

Untitled 1

Chairman of the Board of Managers

Dr. Peter Kiener is an experienced veteran in pharmaceutical…

Somu Photo

Member, Board of Managers

Somu Subramaniam, Member, Board of Managers

Clinical Advisory Board